BioSpace News Archive

InMode Ltd. (Nasdaq: INMD) (“InMode”), a leading global provider of innovative medical technologies, is pleased to announce that it has received clearance from the China National Medical Products Administration NMPA - (previously known as CFDA) for two proprietary InMode radiofrequency platforms - the InMode RF platform and the InMode

Synapse Medicine has announced that it has raised 8 million dollars , spearheaded by the MACSF, a leading insurance provider for healthcare professionals, and with the support of XAnge, BNP Paribas, BPI, and Nicolas Dessaigne, co-founder of Algolia. The purpose of this move is to continue the development of its leading-edge medica

Insmed Incorporated, a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, announced the granting of inducement awards to 11 new employees.

Two flexible financing solutions make essential pet care more affordable in the wake of COVID-19

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, today announced that as a result of continued clinical progress, the Israel Innovation Authority (IIA) has extended its previously awarded development

Company to present inaugural award at Controlled Release Society 2021 Annual Meeting to honor mid-career scientist

Approval also includes extending the Nucleus 7 Sound Processor to the first U.S. cochlear implant recipients, Custom Sound Pro fitting software to enhance support for hearing professionals

Adial Pharmaceuticals, Inc. today announced that it has received approvals in Sweden and Estonia to commence the Company’s landmark ONWARD™ pivotal Phase 3 clinical trial to investigate its lead drug candidate, AD04, as a therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in persons with certain target genotypes related to the serotonin transporter and receptor genes.

ANI Pharmaceuticals, Inc. (“ANI”) (Nasdaq: ANIP) today announced the acquisition of Fluconazole Tablets USP, 50mg, 100mg, 150mg, and 200mg from a private company for $3.0 million . The current annual U.S. market for this product is approximately $40 million , according to IQVIA/IMS Health. Patrick Walsh , ANI’s Interim Preside

Data from Phase 3 LIBERTY program show improvement in patient-reported outcomes in addition to improvement in hemoglobin levels in anemic women Detailed data from ovulation inhibition study demonstrate 100% ovulation inhibition and 100% return of ovulation upon treatment discontinuation Findings presented during European Society of Human Reproduction and Embryology (ESHRE) virtual 36th Annual Meeting taking place July 5-8, 2020